Breathe Well Live Well
 Economic Times |
India revokes patent for Merck asthma drug
Economic Times NEW DELHI: India has revoked a patent for an asthma drug held by US-based Merck following a challenge from local pharmaceutical giant Cipla, marking a new blow to global drug firms in the Indian market. The development is the latest in a string of … India revokes patent on Merck asthma drug Merck loses patent for asthma drug India Revokes Patent on Merck Asthma Drug -Reuters |
View full post on asthma – Google News
|
India revokes patent on Merck & Co asthma drug
Yahoo! News (blog) MUMBAI (Reuters) – India has revoked a patent granted to an asthma drug made by Schering Corp, later bought by U.S.-based Merck & Co, citing lack of invention, after Indian drugmaker Cipla Ltd challenged an earlier decision. The move is the latest in a … |
View full post on asthma – Google News
|
India revokes patent on Merck & Co asthma drug
Reuters MUMBAI (Reuters) – India has revoked a patent granted to an asthma drug made by Schering Corp, later bought by U.S.-based Merck & Co, citing lack of invention, after Indian drugmaker Cipla Ltd challenged an earlier decision. The move is the latest in a … |
View full post on asthma – Google News
 Proactive Investors USA & Canada |
Merck 3Q profit up 2 pct despite sales dip from generic competition to asthma …
Washington Post Drugmaker Merck & Co. said Friday that third-quarter profit rose 2 percent as reduced spending on overhead offset lower sales due to new generic competition for its top-selling drug, Singulair. The maker of diabetes pill Januvia beat Wall Street's … Merck tops view, newer drugs cushion asthma drug blow Merck Q3 earnings edge up despite decline in sales Merck's Profit Rises 2.2% |
View full post on asthma – Google News
 Globe and Mail |
Merck 3Q profit up 2 pct despite sales dip from generic competition to asthma …
Newser The maker of diabetes pill Januvia beat Wall Street's profit expectations. The company also narrowed its 2012 profit forecast, to a range of $2.08 to $2.24 per share, from its July forecast of $2.04 to $2.30. Merck, based in Whitehouse Station, N.J … Merck tops view, newer drugs cushion asthma drug blow Merck posts mixed results for third quarter MERCK & CO., INC. : Merck 3rd-Quarter Profit Up 2.2%; Narrows Year View |
View full post on asthma – Google News
 MedPage Today |
Merck & Co's asthma drug Singulair faces US generic onslaught
PMLiVE The Food and Drug Administration (FDA) has approved the first generic versions of Merck & Co's blockbuster asthma and allergy drug Singulair. The US regulator granted ten companies licences to market their own version of Singulair (motelukast) for use … Israel : TEVA bags approval from FDA to market generic asthma treatment … New generic Singulair could save asthma sufferers big bucks Generic Singulair Approved |
View full post on asthma – Google News
|
Merck Frosst loses information-protection appeal
Vancouver Sun The Supreme Court of Canada on Friday ruled that the federal government was entitled to release information the company had given it about an asthma drug more than a decade ago. "Merck has not shown that the Federal Court of Appeal erred in the … |
View full post on asthma – Google News
|
Merck settles Mass. Medicaid fraud claims for $24M
Sacramento Bee AP BOSTON — Drugmaker Merck & Co. will pay Massachusetts $24 million to settle a civil lawsuit accusing a former subsidiary of causing the state to overpay pharmacists for a widely used asthma medication. Attorney General Martha Coakley said Tuesday … Merck to pay Mass. $24M in Medicaid fraud settlement |
View full post on asthma – Google News
|
Merck Dulera shows efficacy in COPD treatment
Pharmaceutical Business Review Dulera Inhalation Aerosol, which is used to treat asthma combines mometasone furoate, an inhaled corticosteroid, and formoterol fumarate, a long-acting beta2-agonist. The two 26-week, multicenter, double-blind, placebo controlled trials comprising 2251 … Merck Announces Presentation of Phase III Investigational Studies Evaluating … |
View full post on asthma – Google News
|
Merck Announces Presentation of Phase III Investigational Studies Evaluating …
MarketWatch (press release) DULERA is indicated in the United States for the treatment of asthma in patients 12 years and older.(1) It is not indicated for the relief of acute bronchospasm or for the treatment of COPD. A supplemental new drug application (sNDA) for DULERA for the … |
View full post on asthma – Google News